HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics (NASDAQ:HTGM) in a report released on Wednesday morning. The firm currently has a buy rating on the medical research company’s stock.
Other research analysts have also recently issued reports about the company. Zacks Investment Research upgraded HTG Molecular Diagnostics from a hold rating to a buy rating and set a $2.50 price objective for the company in a research note on Wednesday, November 15th. ValuEngine upgraded HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. HTG Molecular Diagnostics currently has an average rating of Hold and a consensus price target of $5.25.
HTG Molecular Diagnostics (NASDAQ HTGM) opened at $2.07 on Wednesday. HTG Molecular Diagnostics has a 12 month low of $1.20 and a 12 month high of $13.25. The stock has a market capitalization of $22.21 and a PE ratio of -0.81.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
What are top analysts saying about HTG Molecular Diagnostics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for HTG Molecular Diagnostics and related companies.